Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab maintenance study in Crohn's disease
2016-003191-50Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc.. Started May 2017; status: active.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2016-003191-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003191-50.